PLS shares (ASX: PLS) fell 5.41% to A$3.50 ahead of the weekend, extending what has been a difficult period for bulls, down 48% since the start of June. After rallying 56.38% YTD up to that point, the reversal has been sharp, and with a strength that is not slowing, as 39.98 million shares changing hands today can attest.

Such is maths, the 48% drawdown from June leaves holders down 18.79% YTD, with the PLS share price right at the foot of the 2026 range. Whilst this has been a year of two halves so far, zooming out a little gives a little more perspective, with the 1 year chart below showing gains of 30.60% on a TTM basis.

Recent Financials

Only weeks ago, PLS delivered a standout FY26 result that saw record concentrate production of 879,000 tonnes, up 17% year on year, with revenue and EBITDA surging and FY27 production guidance lifted into the 1.03 to 1.10 million tonne range. The fact that the stock keeps slipping anyway suggests the market’s focus has moved past what the company has just done and on to what it is promising to do next.

That promise is expensive, with the company shifting into its P1000 operating model through the restart of the Ngungaju plant, and it has committed about A$175 million of pre-FID spending on the P2000 project, which could roughly double Pilgangoora’s capacity to around 2 million tonnes a year. Feasibility outcomes are due in the December quarter, with first ore not expected until around mid-2029 on a project carrying a price tag in the region of A$1.2 billion.

The broader conversation around lithium is not helping the stock in the short term, with spodumene prices down. The sector narrative has shifted from a volume and capacity race to a debate about cost discipline and cycle timing, and PLS’ expansion-heavy story sits right in the middle of it. Its customer base remains heavily linked to China, which adds another layer of sensitivity to demand and policy signals.

 

Top Australian Brokers

The Setup From Here

Looking to the analyst community for clues, and all would appear positive, with an average price target at A$5.10 implying upside of 45% from here. But the technical setup says something else entirely, with the share price below the 50-day moving average at A$4.52, and the 200-day at A$4.99. The 20-day EMA is also below the 50-day equivalent, suggesting in technical terms what you can see with the eye on the chart, that of an established downtrend.

If may well take spodumene price shifts to change the narrative near-term, whilst a clean set of P2000 feasibility outcomes in the December quarter would also be well received. At a 2026 low, and seemingly struggling to find a floor, this upcoming week could be a big one. The stock had previously met resistance between A$3.40-A$3.50 during each of the past two years, making this a key price zone to watch for support, just as provided in early 2024. A glance at the 3 year chart with weekly candles below makes this clear, along with the forming of a head and shoulders pattern. Plenty to watch.

Bull Case:

  • Record FY26 production and surging EBITDA underpin strong current cash generation.
  • FY27 guidance lifted, with Ngungaju restart adding tangible near-term tonnes.
  • Consensus target of A$5.10 implies roughly 44% upside from today’s price.

Bear Case:

  • Established downtrend, with price below both 50-day and 200-day moving averages.
  • P2000 capex near A$1.2b, first ore around mid-2029, raises execution risk.
  • High beta of 2.17 magnifies losses during lithium and China sentiment wobbles.
The Bull Team
The Bull Team is a group of finance writers and journalists that provide commentary and insights on the Australian stock market and beyond.